| 1 |
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet
|
31 Oct 2013 |
955 |
| 2 |
The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
Christopher H. Gibbons, Peter N. Schmidt, Italo Biaggioni et al. · Journal of Neurology
Open access |
3 Jan 2017 |
455 |
| 3 |
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
Joseph J. Jankovic, Ira J. Goodman, Beth Safirstein et al. · JAMA Neurology
Open access |
18 Jun 2018 |
303 |
| 4 |
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
Michael A. Schwarzschild et al. · JAMA Neurology
Open access |
Feb 2014 |
242 |
| 5 |
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Christopher H. Gibbons et al. · JAMA
Open access |
20 Mar 2024 |
199 |
| 6 |
Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
Wolfgang Hermann Oertel, Karla Maria Eggert, Rajesh Pahwa et al. · Movement Disorders
Open access |
21 Aug 2017 |
168 |
| 7 |
Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser et al. · Movement Disorders
Open access |
4 Feb 2015 |
153 |
| 8 |
Droxidopa for the S hort‐ T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B )
Robert A. Hauser, Stuart Isaacson, Jerome P. Lisk et al. · Movement Disorders
Open access |
9 Dec 2014 |
150 |
| 9 |
A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease
François Tison, Charlotte Keywood, Mark Wakefield et al. · Movement Disorders
|
23 May 2016 |
141 |
| 10 |
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
C. Warren Olanow, Stewart Alan Factor, Alberto J. Espay et al. · The Lancet Neurology
|
6 Dec 2019 |
132 |
| 11 |
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Peter A. LeWitt, Robert A. Hauser, Rajesh Pahwa et al. · The Lancet Neurology
|
18 Jan 2019 |
129 |
| 12 |
Haplotypes and gene expression implicate the MAPT region for Parkinson disease
Jennifer E. Tobin et al. · Neurology
Open access |
28 May 2008 |
112 |
| 13 |
The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study
Jeanne C. Latourelle et al. · BMC Medicine
Open access |
5 Nov 2008 |
108 |
| 14 |
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
Ana Westenberger et al. · Brain
Open access159 authors |
14 Jun 2024 |
102 |
| 15 |
Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A)
Robert A. Hauser, L. Arthur Hewitt, Stuart Isaacson · Journal of Parkinson s Disease
Open access |
2014 |
98 |
| 16 |
Sublingual apomorphine (APL‐130277) for the acute conversion of OFF to ON in Parkinson's disease
Robert A. Hauser, C. Warren Olanow, Bruce Dzyngel et al. · Movement Disorders
Open access |
19 Jul 2016 |
82 |
| 17 |
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Alberto J. Espay et al. · The Lancet Neurology
123 authors |
15 Mar 2024 |
80 |
| 18 |
Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
Stuart Isaacson, Mark Lew, William G. Ondo et al. · Movement Disorders Clinical Practice
Open access |
25 May 2016 |
79 |
| 19 |
Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor
Stuart Isaacson et al. · Tremor and Other Hyperkinetic Movements
Open access |
14 Aug 2020 |
77 |
| 20 |
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease
Ronald F. Pfeiffer, Stuart Isaacson, Rajesh Pahwa · Parkinsonism & Related Disorders
Open access |
11 May 2020 |
76 |
| 21 |
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults
Stuart Isaacson, William G. Ondo, Carlayne E. Jackson et al. · JAMA Neurology
Open access |
13 Jan 2020 |
70 |
| 22 |
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
Robert A. Hauser, Stephane R. Heritier, Gerald J. Rowse et al. · Clinical Neuropharmacology
Open access |
23 Jun 2016 |
63 |
| 23 |
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
Michel Peterschmitt et al. · Journal of Parkinson s Disease
Open access |
10 Dec 2021 |
62 |
| 24 |
Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel
Rajesh Pahwa, Stuart Isaacson, Diego R. Torres‐Russotto et al. · Expert Review of Neurotherapeutics
|
23 Jul 2018 |
62 |
| 25 |
Tardive Dyskinesia in Older Persons Taking Antipsychotics
Leslie Citrome, Stuart Isaacson, Danielle Larson et al. · Neuropsychiatric Disease and Treatment
Open access |
Oct 2021 |
57 |
| 26 |
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study
Stuart Isaacson, Babak Boroojerdi, Olga Waln et al. · Parkinsonism & Related Disorders
|
29 Jan 2019 |
57 |
| 27 |
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations
Richard Jackson, Matthew N. Brams, Leslie Citrome et al. · Neuropsychiatric Disease and Treatment
Open access |
May 2021 |
56 |
| 28 |
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis
Clive G. Ballard, Stuart Isaacson, Roger Mills et al. · Journal of the American Medical Directors Association
|
Aug 2015 |
56 |
| 29 |
Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease
Robert A. Hauser, Dee E. Silver, Azhar Choudhry et al. · Movement Disorders
|
11 Jun 2014 |
56 |
| 30 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner et al. · Journal of Parkinson s Disease
Open access |
4 Aug 2017 |
52 |
| 31 |
Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials
Jimin Ren, Richard B. Dewey, Austin Rynders et al. · Journal of Nanobiotechnology
Open access |
12 Dec 2023 |
51 |
| 32 |
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease
Michael Camilleri et al. · Annals of Internal Medicine
Open access |
7 Nov 2022 |
50 |
| 33 |
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease
Robert A. Hauser, Stuart Isaacson, Aaron L. Ellenbogen et al. · Parkinsonism & Related Disorders
Open access |
30 Mar 2019 |
50 |
| 34 |
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease
Robert A. Hauser, Alberto J. Espay, Aaron L. Ellenbogen et al. · JAMA Neurology
Open access |
14 Aug 2023 |
48 |
| 35 |
Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects
Kelly E. Lyons, Joseph H. Friedman, Neal S. Hermanowicz et al. · Clinical Neuropharmacology
|
2010 |
48 |
| 36 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
Angelo Antonini, Rajesh Pahwa, Per Odin et al. · CNS Drugs
ReviewOpen access |
21 Nov 2022 |
45 |
| 37 |
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
Robert A. Hauser, Nobutaka Hattori, Hubert H. Fernandez et al. · Journal of Parkinson s Disease
Open access |
3 Sep 2021 |
45 |
| 38 |
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
Tien Dam et al. · npj Parkinson s Disease
Open access198 authors |
27 Sep 2024 |
44 |
| 39 |
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
Stuart Isaacson, Robert A. Hauser, Rajesh Pahwa et al. · Clinical Parkinsonism & Related Disorders
Open access |
2023 |
44 |
| 40 |
Targeting neurons in the gastrointestinal tract to treat Parkinson's disease
Robert A. Hauser et al. · Clinical Parkinsonism & Related Disorders
Open access |
2019 |
44 |
| 41 |
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 ‐Year Data from the Open‐Label BeyoND Study
Werner H Poewe et al. · Movement Disorders
Open access |
8 Sep 2021 |
42 |
| 42 |
Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303)
Stuart Isaacson, Holly A. Shill, Steven A. Vernino et al. · Journal of Parkinson s Disease
Open access |
4 Aug 2016 |
42 |
| 43 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
Clive G. Ballard, David L. Kreitzman, Stuart Isaacson et al. · Parkinsonism & Related Disorders
|
28 Jun 2020 |
40 |
| 44 |
Replication of association between ELAVL4 and Parkinson disease: the GenePD study
Anita L. DeStefano et al. · Human Genetics
Open access |
28 Jun 2008 |
40 |
| 45 |
Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa
Stuart Isaacson, Julia Skettini · Vascular Health and Risk Management
Open access |
Apr 2014 |
39 |
| 46 |
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective
Stuart Isaacson, Stanley E. Fisher, Fiona Gupta et al. · Expert Review of Neurotherapeutics
|
4 Nov 2016 |
38 |
| 47 |
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection
Robert A. Hauser, Stuart Isaacson, Thomas Clinch · Parkinsonism & Related Disorders
|
27 Aug 2014 |
38 |
| 48 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
Caroline M. Tanner, Rajesh Pahwa, Robert A. Hauser et al. · Journal of Parkinson s Disease
Open access |
17 Jan 2020 |
36 |
| 49 |
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
Felix Agbo, Stuart Isaacson, Ramon A. Gil et al. · Neurology and Therapy
Open access |
15 May 2021 |
30 |
| 50 |
Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Stuart Isaacson, Steven A. Vernino, Adam E. Ziemann et al. · Journal of the American Society of Hypertension
Open access |
4 Aug 2016 |
30 |